Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2007-10-02
2007-10-02
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S183000, C435S235100, C435S236000, C536S023200, C536S023720, C424S188100, C424S208100, C424S093200, C514S04400A
Reexamination Certificate
active
09959936
ABSTRACT:
The object of the present invention is to provide a screening method of a new integrase inhibitor being able to inhibit an HIV infection before the reverse transcription step and having a pharmaceutical site of action totally different from those of traditional integrase inhibitors, a new integrase inhibitor being obtainable by the screening method, and pharmaceutical constituents containing the integrase inhibitor and DNA encoding the integrase inhibitor being greatly expected as new remedies for AIDS. A peptide which specifically binds to a peptide at N-terminal domain of retroviral integrase was screened by phage display method, and as a result of the screening, a peptide being able to inhibit the infection and the proliferation of retroviruses such as HIV-1 before the reverse transcription reaction is obtained.
REFERENCES:
patent: 0692032 (1998-05-01), None
patent: 8-505042 (1996-06-01), None
patent: 9-508369 (1997-08-01), None
patent: WO94/06454 (1994-03-01), None
patent: WO94/06454 (1994-03-01), None
patent: WO94/23058 (1994-03-01), None
patent: WO95/19772 (1995-01-01), None
patent: WO98/52970 (1998-11-01), None
Mazumder et al. Biochemistry 35:13762-13771, 1996.
Desrosiers (Nature Medicine, Mar. 2004, 10(3): 221-223).
Leavitt et al (Journal of Biological Chemistry 268:2113-2119, 1993).
Masuda et al (Journal of Virology 69:6687-6696, 1995).
Cannon et al (Journal of Virology 68:4768-4775, 1994).
Engelman et al (Journal of Virology 69:2729-2736, 1995).
Wiskerchen et al (Journal of Virology 69:376-386, 1995).
Vincent et al (Journal of Virology 67:425-437, 1993).
Leavitt et al (Journal of Virology 70:721-728, 1996).
Nakamura et al (Biochemical and Biophysical Research Communications 239:715-722, 1997).
Leavitt, et al. J Biol Chem (1993) 268:2113-2119.
Leavitt, et al. J Virol. (1996) 70:721-728.
Mazumder et al., “Inhibition of the Human Immunodeficiency Virus Type 1 Integrase by Guanosine Quartet Structures”,Biochemistry,vol. 35, 1996, pp. 13762-13771.
Masuda et al., “Genetic Analysis of Human Immunodeficiency Virus Type 1 Integrase and the U3att Site: Unusual Phenotype of Mutants in the Zinc Finger-Like Domain”,Journal of Virology,vol. 69, No. 11, Nov. 1995, pp. 6687-6696.
Katz, et al., “The Retroviral Enzymes”Annu. Rev. Biochem,vol. 63, 1994, pp. 133-173.
Engelman et al., “Identificationof Conserved Amino Acid Residues Critical for Human Immunodeficiency Virus Type 1 Integrase Function In Vitro”,Journal of Virology,vol. 66, No. 11, Nov. 1992, pp. 6361-6369.
Kulkosky et al., “Residues Critical for Retroviral Integrative Recombination in a Region That Is Highly Conserved among Retroviral/Retrotransposon Integrases and Bacterial Insertion Sequence Transposases”,Molecular and Cellular Biology,vol. 12, No. 5, May 1992, pp. 2331-2338.
LaFemina, et al., “Substrate Specificity of Recombinant Human Immunodeficiency Virus Integrase Protein”,Journal of Virology,vol. 65, No. 10, Oct. 1991, pp. 5624-5630.
Eijelenboom, et al., “The DNA-binding domain of HIV-1 integrase has an SH3-like fold”,Nature Structural Biology,vol. 2, No. 9, Sep. 1995, pp. 807-810.
Lodi, et al. “Solution Structure of the DNA Binding Domain of HIV-1 Integrase”,Biochemistry,vol. 34, 1995, pp. 9826-9833.
Puras et al., “Characterization of the minimal DNA-binding domain of the HIV integrase protein”,Nucleic Acids Research,vol. 22, No. 20, 1994, pp. 4125-4131.
Zheng, et al. “Zinc folds the N-teminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity”,Proc. Natl. Acad. Sci. USA,vol. 93, Nov. 1996, pp. 13659-13664.
Cai et al., Solution structure of the N-terminal zinc binding domain of HIV-1 integrase,Nature Structural Biology,vol. 4, No. 7, Jul. 1997, pp. 567-577.
Adachi, et al., “Production of Acquired Immunodeficiency Syndrome-Associated Retrovirus in Human and Nonhuman Cells Transfected with an Infectious Molecular Clone”,Journal of Virology,vol. 59, No. 2, Aug. 1986, pp. 284-291.
Tahei Nakamura et al., “Lack of Infectivity of HIV-1 Integrase Zinc Finger-like Domain Mutant with Morphologically Normal Maturation”, Biochemical and Biophysical Research Communication, 1997, pp. 715-722, vol. 239, Academic Press.
Bente M. Nilsen et al., “Monoclonal Antibodies against Human Immunodeficiency Virus Type 1 Integrase: Epitope Mapping and Differential Effects on Integrase Activities In Vitro”, Journal of Virology, Mar. 1996, pp. 1580-1587, vol. 70, No. 3, American Society for Microbiology.
Pnina Levy-Mintz et al., “Intracellular Expression of Single-Chain Variable Fragments To Inhibit Early Stages of the Viral Life Cycle by Targeting Human Immunodeficiency Virus Type 1 integrase”, Journal of Virology, Dec. 1996, pp. 8821-8832, vol. 70, No. 12, American Society for Microbiology.
Andrew D. Leavitt et al., “Human Immunodeficiency Virus Type 1 Integrase Mutants Retain In Vitro Integrase Activity yet Fail To Integrate Viral DNA Efficiently during Infection”, Feb. 1996, pp. 721-728, vol. 70, No. 2, American Society for Microbiology.
Karen A. Vincent, et al., “Characterization of Human Immunodeficiency Virus Type 1 Integrase Expressed inEscherichia coliand Analysis of Variants with Amino-Terminal Mutations”, Jan. 1993, pp. 425-437, vol. 67, No. 1, American Society for Microbiology.
Kannagi Mari
Masuda Takao
Campell Bruce R.
Hobbs Ann S.
Japan Science and Technology Agency
Kinberg Robert
Snyder Stuart W.
LandOfFree
Viral infection inhibitor targeting integrase N-terminal domain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viral infection inhibitor targeting integrase N-terminal domain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral infection inhibitor targeting integrase N-terminal domain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3863061